Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Manchester Capital Management LLC

Manchester Capital Management LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 33.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,999 shares of the biopharmaceutical company’s stock after selling 7,579 shares during the period. Manchester Capital Management LLC’s holdings in Gilead Sciences were worth $1,385,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of GILD. AMF Tjanstepension AB raised its stake in Gilead Sciences by 14.7% during the third quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after purchasing an additional 51,390 shares during the period. Creative Planning raised its stake in shares of Gilead Sciences by 16.1% in the 3rd quarter. Creative Planning now owns 219,045 shares of the biopharmaceutical company’s stock valued at $18,365,000 after acquiring an additional 30,451 shares during the period. Swedbank AB raised its stake in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after acquiring an additional 189,622 shares during the period. SPC Financial Inc. raised its stake in shares of Gilead Sciences by 11.0% in the 3rd quarter. SPC Financial Inc. now owns 5,530 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 550 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $25,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $104.08 on Friday. The company’s 50 day moving average price is $93.63 and its 200 day moving average price is $87.37. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $106.69. The company has a market capitalization of $129.71 billion, a PE ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 3.04%. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GILD shares. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday. Mizuho raised their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, Citigroup started coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.33.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 137,676 shares of the company’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the sale, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at approximately $17,502,415.06. This represents a 44.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 over the last ninety days. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.